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Warfarin Versus Aspirin in Preventing
Tunneled Hemodialysis Catheter Thrombosis:
A Prospective Randomized Study
Ibrahiem Saeed Abdul-Rahman, Abdulla K. Al-Howaish
Background: Vascular access complications are the greatest cause of morbidity and hospitalization in
hemodialysis patients. The most frequent complication of central catheters used for hemodialysis is dysfunction
due to thrombosis. Tunneled hemodialysis catheter thrombosis represents a major medical and economic burden.
Although systemic anticoagulation is commonly prescribed to prevent thrombosis and malfunction of the
vascular access during hemodialysis, there are only limited data regarding the effect of systemic anticoagulation
or antiplatelet activation in between dialysis sessions.
Methods: This randomized prospective study aimed to evaluate whether anticoagulation with adjusted-dose
warfarin or low dose aspirin is associated with a long-term improvement of tunneled hemodialysis catheter
thrombosis outcome. Among the 58 patients included in the study, 20 were placed on daily warfarin and 19 on
aspirin, while 19 were used as control.
Results: Among patients receiving warfarin, 18 (90%) achieved adequate anticoagulation (i.e. INR value within
target range), and four (20%) had at least one episode of catheter malfunction due to catheter thrombosis. Four
(21.1%) patients on aspirin had one or more episodes of catheter malfunction because of central venous catheter
thrombosis (p > 0.05), while nine (47.4%) out of the 19 control patients had tunneled catheter thrombosis with
catheter malfunction (p < 0.01). Malfunction-free catheter survival at 12 months was 75% in the warfarin
group, 68.4% in the aspirin group, and 36.8% in the control group. There was no statistically significant difference
between the warfarin and aspirin groups, while the difference between the warfarin or aspirin group and the
control group was statistically significant (p < 0.01).
Conclusion: These results suggest that both warfarin and aspirin are effective in preventing tunneled hemodialysis
catheter thrombosis and increasing long-term malfunction-free catheter survival. [Hong Kong J Nephrol 2007;
9(1):23–30]
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INTRODUCTION
Vascular access complications are the greatest cause
of morbidity and hospitalization in hemodialysis
patients [1,2]. The most frequent complication of
vascular access is dysfunction due to thrombosis [1].
This applies also to tunneled hemodialysis catheters
(THC), which often fail as a result of central venous
thrombosis, luminal obstructive thrombus, or formation
of a fibrin sheath at its tip. This accounts for
considerable morbidity and mortality with an estimated
annual cost close to one billion dollars in the United
States [3]. Moreover, vascular access complications
mainly consisting of thrombotic events are responsible
for 17–25% of all hospitalizations in dialysis patients
[4,5]. In the last 10 years, tunneled central venous
catheters have been increasingly utilized in chronic
hemodialysis patients, sometimes in the place of
arteriovenous fistulas. They have gained popularity for
their unquestioned advantages, such as technique
feasibility, and the possibility for immediate use. In
spite of different protocols for catheter tip positioning,
anticoagulation during hemodialysis and application of
thrombolytic agents, tunneled central venous catheter
dysfunction defined as failure to maintain a blood flow
of at least 250 mL/min remains the Achilles’ heel of
the system. Considering the magnitude of the problem
of thrombosis in patients using tunneled catheters for
dialysis access, prophylaxis is important and must begin
at the time of catheter usage. In addition to using an
infection-prevention protocol at the end of the dialysis
session, a thrombosis-prevention protocol is also
important. Earlier studies in patients treated for
hematologic malignancy or parenteral nutrition claimed
improved central venous catheter patency rates when
patients were given warfarin on a daily basis [6,7].
Another recent study reported that aspirin was equally
as effective as warfarin in preventing thrombotic events
in THC [8]. The aim of this prospective study was to
evaluate whether systemic anticoagulation with
adjusted-dose warfarin or through inhibition of platelet
activation via aspirin would decrease the incidence of
catheter thrombosis and hence improve long-term
hemodialysis catheter outcome.
PATIENTS AND METHODS
Study design and participants
The study was a randomized prospective double-blind
trial performed in 58 hemodialysis patients during the
period from December 2004 to December 2005.
Patients with tunneled central venous catheter were
randomized into three groups. Group A comprised 20
patients given warfarin, group B comprised 19 patients
given aspirin, and group C was the control group with
19 patients. The study was fully explained to all the
patients, and written consent was obtained from each
of them. The adjusted-dose warfarin was targeting an
international normalized ratio (INR) of 1.5–2.0,
whereas aspirin was prescribed as an 81 mg single dose
per day throughout the study period. Participants were
excluded if they had experienced blood loss requiring
either hospitalization or transfusion in the previous 3
months, demonstrated advanced proliferative diabetic
retinopathy, had life expectancy < 12 months because
of advanced organ-systemic disease or malignancy,
exhibited uncontrolled hypertension (defined as systolic
blood pressure, BP, > 200 mmHg or diastolic BP >
110 mmHg on three different occasions in a period of
2 weeks), demonstrated platelet count < 100,000/cm3,
INR > 1.3, or partial thromboplastin time 5 seconds
longer than control, or demonstrated other medical
conditions that would make anticoagulant or antiplatelet
therapy dangerous. Patients receiving dipyridamole,
sulfinpyrazone, ticlopidine, clopidogrel, or nonsteroid
anti-inflammatory drugs were also excluded. Neither
the details of the randomization sequence nor the
identity of the medication assignment was known to
the participants or the assigned physician.
Outcomes
The primary outcome measure was the time to the first
episode of catheter thrombosis, defined clinically as
the detection of a visible catheter clotting or the inability
to successfully initiate or continue dialysis via the
tunneled central catheter with a blood flow < 250 mL/
min in the absence of other causes of catheter
malfunction. The presence of hemodialysis tunneled
central venous catheter thrombosis was determined by
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a staff member, who was blinded to treatment
allocation. Major bleeding event — as a cause to
discontinue the study — was defined as confirmed
retroperitoneal, intra-articular or cerebral hemorrhage,
or any bleeding episode that resulted in a 2 g/dL
decrease in hemoglobin concentration.
Dialysis procedure
Tinzaparin sodium (LEO Pharma A/S, Ballerup,
Denmark) was given as a single bolus dose into the
arterial line of the THC at the start of each dialysis
session. At the end of the study, the mean applied
tinzaparin dose was calculated to be 45 ± 15.6 IU/kg in
group A patients, 45 ± 12.1 IU/kg in group B patients,
and 50 ± 9.5 IU/kg in the control group. The dose of
tinzaparin was not pre-decided, but based on clinical
observations. It is our practice to observe closely for
evidence of extracorporeal circuit thrombosis during
the dialysis procedure. The tinzaparin dose would then
be modified accordingly in the next dialysis sessions.
The mean dose for each group was then calculated at
the end of the study. The dialysis sessions were 4–4.5
hours three times per week. A polysulphone high-flux
hollow fiber dialyzer (F50-F60, Fresenius AG, Bad
Homburg, Germany), was used during the study.
Polyurethane bilumen tunneled catheter, 30 cm long, 7
French with two 16-gauge channels (Bard Access
Systems Inc., Salt Lake City, UT, USA) were inserted
in each patient using the Seldinger method. Bicarbonate
dialysate was used in all patients. Catheters were
checked by aspiration at the beginning of each dialysis
session to ensure that there was no clot formation. The
blood flow rate varied between 250–350 mL/min. Blood
flow was recorded by the dialysis machine’s flowmeter.
Statistical analysis
Data are presented as mean ± standard deviation.
Statistical comparison between the different groups of
patients was done using Student’s t test. A p value < 0.05
was considered significant. Analysis was performed
using SPSS (SPSS Inc., Chicago, IL, USA) and the
statistical software program, GraphPad Prism
(GraphPad Software Inc., San Diego, CA, USA).
RESULTS
Clinical characteristics and laboratory data
The clinical characteristics and laboratory data of the
subjects are shown in Tables 1 and 2. There were no
significant differences among the three groups with
respect to sex, age, and percentage of patients with
hypertension and diabetes, Kt/V, blood urea nitrogen
(BUN), serum creatinine, cholesterol, triglycerides,
low-density lipoprotein, high-density lipoprotein,
albumin, initial INR, hematocrit, and platelet count. The
difference in tinzaparin dose among the three groups
was also not statistically significant (p = 0.12).
Treatment and follow-up
INR was measured on a twice weekly basis. The dose
of warfarin given to the warfarin group ranged between
2 mg and 5 mg daily, targeting an INR of 1.5–2.0. The
average achieved INR was 1.7. INR values were above,
within, and below the target range in 25%, 65%, and
10% of cases, respectively. Aspirin was given to the
aspirin group as a dose of 81 mg/day. Since there is no
dependable laboratory test for follow-up of antiplatelet
activity, patients were closely monitored for its serious
side effects. None of the 58 patients experienced major
bleeding episodes, and hence there were no significant
changes between the initial and final hemoglobin and
hematocrit levels in each of the groups (Table 3).
THC thrombosis or malfunction
Among the 58 patients included in the study, 20 were
placed on daily warfarin, 19 on aspirin, and 19
constituted the control group. Among patients receiving
warfarin, 18 (90%) achieved adequate anticoagulation
(i.e. INR value within target range), and four (20%)
had at least one episode of catheter malfunction due to
catheter thrombosis.
Table 1. Clinical characteristics of patients*
Group A (n = 20) Group B (n = 19) Group C (n = 19) p
Age (yr) 48.3 ± 11.5 44.7 ± 7.4 45.4 ± 9.5 > 0.05†‡§
Sex (female/male) 8/12 9/10 7/12 > 0.05†‡§
Weight at baseline (kg) 77.5 ± 6.1 69.8 ± 7.7 80.5 ± 4.5 > 0.05†‡§
DM, n (%) 6 (30) 6 (31.6) 8 (42.1) > 0.05†‡§
HPN, n (%) 13 (65) 10 (52.6) 9 (47.4) > 0.05†‡§
Days of dialysis prior to randomization 26 ± 15.3 19 ± 11.7 24 ± 12.3 > 0.05†‡§
Site of TCVC (IJV/femoral) 17/3 18/1 19/0 > 0.05†‡§
Dialysis tinzaparin dose (IU/kg) 45 ± 15.6 45 ± 12.1 50 ± 9.5 0.12†‡§
*Data presented as mean ± standard deviation or n (%);†Group A vs. group B; ‡group A vs. group C; §group B vs. group C. DM = diabetes
mellitus; HPN = hypertension; TCVC = tunneled central venous catheter; IJV = internal jugular vein.
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Four (21.1%) patients on aspirin had one or more
episodes of catheter malfunction because of central
venous catheter thrombosis (p > 0.05), while nine
(47.4%) out of the 19 control patients had THC
thrombosis with catheter malfunction (p < 0.01).
Malfunction-free catheter survival at 12 months was
75% in the warfarin group, 68.4% in the aspirin group,
and 36.8% in the control group. There was no
statistically significant difference between the warfarin
and aspirin groups, while the difference between the
warfarin or aspirin group and the control group was
statistically significant (p < 0.01) (Table 4).
DISCUSSION
THCs often fail as a result of thrombosis of the lumen
and/or thrombosis of the vein, with incidence rates of
up to 63% [9]. Several types of thrombus may be seen,
differing by location and supposed mechanism of
formation. The most common offender, however, is the
fibrin sheath thrombus, that leads to significant
malfunction of the THC. Catheter malfunction is
defined as failure to attain and maintain an
extracorporeal blood flow sufficient to perform
hemodialysis without significantly lengthening the
hemodialysis treatment. The Kidney Disease Outcome
Quality Initiative (K/DOQI) defines sufficient
extracorporeal blood flow as ≥ 300 mL/min [10]. With
newer catheter designs, this goal is attainable, and
nephrologists should not settle for less in patients
requiring maintenance hemodialysis.
Thrombosis is a common problem; the mean
patency rate for these catheters has been reported to
range from 73 to 84 days [11,12], with most losses being
due to thrombosis. The specific factors leading to
catheter thrombosis in any given case are seldom
obvious. Only rarely does one encounter a patient with
a definable state of hypercoagulability; most cases of
thrombosis can only be attributed to activation of the
contact  coagulation cascade by a relatively
bioincompatible device [13].
How often a THC results in central vein thrombosis
is uncertain. Frequencies as low as 2% [14] and as high
as 63.5% [15] have been reported. The reported
frequency appears to depend on whether the thrombosis
is searched for systemically or only when it becomes
symptomatic. It is clear that symptomatic central vein
thrombosis is not common, but when it does occur, the
symptoms can be dramatic. Although the presence of a
central vein thrombus may be confirmed by ultrasound,
the diagnosis is generally based on the clinical picture
presented by the patient. Locally, the thrombus incites
an inflammatory reaction. The patient generally
presents with pain and tenderness in the base of the
neck, the supraclavicular fossa, and the shoulder area.
Obstruction of the thoracic veins leads to swelling of
the ipsilateral extremity. None of these clinical features
Table 2. Laboratory parameters of patients*
Group A (n = 20) Group B (n = 19) Group C (n = 19) p
Kt/V 1.8 ± 0.3 1.6 ± 0.4 1.7 ± 0.3 NS†‡§
BUN (mg/dL) 86.4 ± 11.2 79.8 ± 17.6 80.8 ± 14.5 NS†‡§
Cr (mg/dL) 14.2 ± 9.7 12.6 ± 11.4 13.7 ± 10.2 NS†‡§
Albumin (g/dL) 3.7 ± 0.4 4.1 ± 0.2 3.9 ± 0.4 NS†‡§
CHOL (mg/dL) 198 ± 22.3 203 ± 16.8 187 ± 20.7 NS†‡§
TG (mg/dL) 218 ± 19.5 191 ± 24.7 211 ± 16.7 NS†‡§
LDL (mg/dL) 130 ± 9.4 136 ± 8.8 122 ± 11.1 NS†‡§
Hematocrit (%) 30.4 ± 2.8 29.3 ± 2.1 33.3 ± 3.4 NS†‡§
Platelets (104/µL) 21.9 ± 5.5 22.3 ± 4.9 19.7 ± 5.3 NS†‡§
*Data presented as mean ± standard deviation or n (%); †Group A vs. group B; ‡group A vs. group C; §group B vs. group C. Kt/V = indicator
of hemodialysis adequacy; NS = non-significant; Cr = creatinine; CHOL = cholesterol; TG = triglycerides; LDL = low-density lipoprotein.
Table 3. Initial and final hemoglobin (Hgb, g/dL) and hematocrit (HCT, %) levels in the different patient groups
Group A Group B Group C
Hgb HCT Hgb HCT Hgb HCT
Initial Final Initial Final Initial Final Initial Final Initial Final Initial Final
9.8 ± 1.8 9.5 ± 2.0 30.4 ± 2.8 29 ± 3.3 8.9 ± 2.1 8.8 ± 1.7 29.3 ± 2.1 29.5 ± 1.8 10 ± 1.9 9.9 ± 1.5 33.3 ± 3.4 32.7 ± 2.7
p > 0.05 p > 0.05 p > 0.05 p > 0.05 p > 0.05 p > 0.05
The p value refers to the difference between the initial and final values in each group.
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were present in our patients. Most catheter flow
problems are related to intrinsic thrombi. These thrombi
may be intraluminal, attaching to the catheter tip, or
they may surround the catheter in a sheath-like
configuration [16]. When an inadequate volume of
heparin is instilled into the catheter after dialysis or
when heparin escapes from the catheter lumen between
dialysis sessions, blood can enter the catheter and form
an intraluminal thrombus. When this occurs, the
catheter may become partially or completely occluded.
Attempts at aspiration, as with our technique, usually
shows clotted blood [17].
Many THC have side holes at the tip of the arterial
limb. Unfortunately, the portion of the catheter from
the side holes to the tip does not retain heparin and a
thrombus can form at the catheter tip. A tip thrombus
may be occlusive or it may act as a ball valve. Preventive
measures that are commonly used to avoid intraluminal
thrombosis are largely subverted by the presence of the
side holes [18]. Fibrin sheath thrombus commonly
forms in association with the THC and it probably
accounts for most late failures of THCs [19]. The term
“fibrin sheath” refers to a sleeve of fibrin that surrounds
the catheter starting at the point where it enters the vein.
Although occasional clinical reports demonstrated the
presence of fibrin and platelets as the main components
of the sheath, an experimental animal study showed
that the sheath starts as red thrombus containing fibrin
and it may be facilitated by the presence of central vein
thrombosis [20]. Measures against venous thrombosis,
that include both anticoagulants as well as antiplatelets,
therefore, may be of value. The fibrin sheath may
actually be continuous with the lining of the catheter
tunnel and is usually loosely attached to the catheter.
As the sheath extends downward, it eventually closes
over the tip of the catheter. In this position, it tends to
interfere with adequate blood flow in one or both
directions [21].
Platelet abnormalities in renal failure are usually
associated with an antithrombotic rather than a
prothrombotic tendency. Diminished platelet
degranulation, reduction in stored platelet adenosine
diphosphate (ADP) and serotonin, and decreased
platelet synthesis of thromboxane are among the
abnormalities that have been demonstrated by in vitro
studies of platelets from patients with renal failure [22–
24]. More recent studies suggest that impaired
activation or decreased numbers of glycoprotein IIb-
IIIa receptors on the platelet membrane results in
reduced platelet binding to von-Willebrand factor and
fibrinogen [25–29]. Recent attention has focused on
the role of nitric oxide in uremic platelet dysfunction.
Nitric oxide inhibits platelet-endothelial and platelet-
platelet interactions, and its inhibition has been shown
to shorten bleeding time in humans [30–32]. However,
it should be noted that while circulating nitric oxide
levels may be increased in renal failure, accumulating
data suggest that uremia is a state of reduced total body
nitric oxide production that may initiate platelet
aggregation in some cases [33]. While the bulk of
experimental data suggest that renal failure is associated
with reduction in platelet activity, enhanced platelet
aggregation during the hemodialysis procedure has been
demonstrated by several investigators [34–36]. This
hemodialysis-associated platelet activation is viewed
as a marker of dialyzer membrane bioincompatibility
and may initiate central venous and catheter thrombosis
[36]. The use of antiplatelet drugs, therefore, as a
prophylaxis against catheter-related thrombotic events
may be justifiable. Our results showed that 21.1% of
our patients on aspirin had one or more episodes of
catheter malfunction because of central venous catheter
thrombosis compared to 47.4% of the control group
(p < 0.01), a result that matches with that of Obialo et
al [8], who also calculated the relative risk of
gastrointestinal bleeding associated with aspirin in
young patients as 0.71 (95% confidence interval, CI,
0.11–4.4, p = 0.7) and  as 1.14 (95% CI, 1.0–1.3, p =
0.008) among elderly aspirin users. Our patients did
not experience gastrointestinal bleeding, although one
could argue that the sample size was relatively small.
Primary treatment of THC malfunction refers to
treatment that can be applied in the hemodialysis
facility. Mechanical treatment to remove the occluding
thrombus using a guidewire [37], Fogarty catheter,
or ureteral biopsy brush [16], has been reported.
Table 4. Comparison of catheter thrombosis and catheter long-term survival among patient groups*
Group A Group B Group C p
Catheter thrombosis at least once 4 (20.0) 4 (21.4) 9 (47.4) < 0.01†
< 0.01‡
NS§
Catheter survival at 12 mo 15 (75.0) 13 (68.4) 7 (36.8) < 0.01†
< 0.05‡
NS§
*Data presented as n (%); †group A vs. group C; ‡group B vs. group C; §group A vs. group B.
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The advantages of the mechanical technique are that it
has a high success rate and produces no systemic effects,
making it safe and relatively inexpensive. However, it
has the disadvantage of not being a permanent solution,
and usually a physician must perform the procedure. If
a fibrin sheath is the cause of catheter malfunction,
mechanical removal of the occlusion is not a long-term
solution. In the setting of THC thrombosis, catheter
exchange is relatively safe and has a high success rate.
A disadvantage is that a new catheter exit wound is
created with some associated risk of bleeding and
infection [38].
Urokinase was used very effectively in the
management of THC dysfunction resulting from
thrombosis [12,39], but since this agent has become
unavailable, tissue plasminogen activator (tPA) has been
used with equal success. Because of regulatory
restraints, an appropriately packaged dose for catheter
use is not yet available. Currently, tPA is available only
in 50 mg vials, so it must be divided into appropriately
sized aliquots before use. Furthermore, these aliquots
must be stored at –20°C until administration. These
factors limit the use of tPA to facilities that have access
to an expert pharmacist and –20°C storage [11,40].
Fibrin sheath stripping has been tried with a good
success rate [11,21,41,42], but the disadvantages are
the cost of the snare and the time required to accomplish
the procedure, and the fact that it is not a permanent
solution to the problem. Because it offers no better
solution than the alternatives and results in higher cost,
this procedure cannot be recommended [43,44].
It follows that, considering the magnitude of the
problem of thrombosis in patients using tunneled
catheters for dialysis access, prophylaxis is important
and must begin at the time of catheter usage. In addition
to using an infection-prevention protocol at the end of
the dialysis session, a thrombosis-prevention protocol
both at the end of dialysis and in between dialysis
sessions is also important. Unfortunately, a reliable
effective means for preventing catheter thrombosis
using systemic anticoagulation has not been described.
Earlier studies [6,7] in patients treated for hematologic
malignancy or parenteral nutrition claimed improved
central venous catheter patency rates when patients
were given 1 mg warfarin, a dose that has discernible
effect on the INR. However, this approach has been
disappointing in preventing further thrombus formation
with hemodialysis catheters. Some centers have used
anticoagulation with warfarin by titrating the dose of
warfarin upward in a stepwise manner until the thrombotic
episodes resolve [46,47]. In one study, the average dose
of warfarin was 2.1 ± 1.6 mg/day with an average INR of
1.5 ± 0.9 [45]. The study however was not controlled.
The study of Twardowski [47] failed to define a safe
and effective INR level that one can aim at. Targeting
an INR value of 1.5–2.0 as in our study seems to be not
only safe, but also effective in preventing central venous
catheter thrombosis (90% of our patients on warfarin
achieved adequate anticoagulation i.e. INR value within
target range, and 80% had thrombosis-free catheter by
the end of the study). Moreover, malfunction-free
catheter survival in our study was more than satisfactory
(catheter survival at 12 months was 75% in group A
and 68.4% in group B, vs. 36.8% in group C, p < 0.01
and p < 0.05, respectively; Figure). Low molecular
weight heparin was used intradialytically for all our
patients, with the minimal doses that could prevent
tubes and/or dialyzer clotting during hemodialysis.
These doses were not decided before but were based
on trial and error. Group C patients needed a relatively
higher dose (although statistically, the difference was
not significant; Table 1), which may be explained by
the lack of anticoagulant or antiplatelet therapy.
At the end, questions remain. How beneficial are
these trials with daily warfarin or aspirin in a setting of
tunneled central vein hemodialysis catheter? Is
intradialytic anticoagulation intensity sufficient to
prevent catheter and central vein clotting? A single
bolus of low molecular weight heparin at the start of
hemodialysis may prevent clot formation, but
subclinical activation of platelets and coagulation may
still occur [48]. Consequently, the relationship between
clinical clotting events and platelet activation and
coagulation before and after hemodialysis is of great
significance. In fact, Sagedal et al clearly demonstrated
that  anticoagulation intensity sufficient  for
Figure. Tunneled hemodialysis catheter survival at 12 months.
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hemodialysis does not prevent activation of coagulation
and platelet aggregation [49]. Moreover, it is well
known that hemodialysis patients have an increased rate
of cardiovascular disease, and that cardiovascular
complications account for > 50% of all deaths in
hemodialysis patients [50,51]. Activation of coagulation
may be associated with cardiovascular events, and
platelet activation may be followed by potential adverse
and serious effects on heart and vessel structure [52].
Warfarin and antiplatelet therapy both reduce the
tendency towards hypercoagulability in dialysis
patients ,  and hence are expected to reduce
cardiovascular complications.
Both aspirin and warfarin are equally effective in
preventing THC and prolonging catheter survival. With
tight exclusion criteria, the risk of major bleeding can
be successfully avoided. We believe that more
prospective, randomized placebo-controlled trials using
antiplatelet or oral anticoagulation therapy are needed
to determine whether the potential benefits of such
therapy outweigh the risk of adverse events. In the
meantime, it seems reasonable to give some form of
anticoagulant therapy based on pathophysiologic
considerations and the high incidence of thrombotic
complications.
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